Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer

Varsavsky, Mariela; Reyes-García, Rebeca; Cortés-Berdonces, María; García-Martín, Antonia; Rozas-Moreno, Pedro; Muñóz-Torres, Manuel

doi:10.1016/j.endonu.2011.07.007

Cited by 11 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin D deficiency or insufficiency is common in the general population and in patients with cancer. [98][99][100] Although vitamin D is clearly important for bone health, evidence for its role in multiple other health outcomes remains uncertain. The Endocrine Society Guidelines recommend using the serum circulating 25(OH) D level, measured with a reliable assay, to evaluate vitamin D status in patients who are at risk for vitamin D deficiency.…”

Section: Nonpharmacologic Componentsmentioning

confidence: 99%

NCCN Task Force Report: Bone Health in Cancer Care

Gralow¹,

Biermann²,

Farooki³

et al. 2013

J Natl Compr Canc Netw

285

176

View full text Add to dashboard Cite

Bone health and maintenance of bone integrity are important components of comprehensive cancer care. Many patients with cancer are at risk for therapy-induced bone loss, with resultant osteoporotic fractures, or skeletal metastases, which may result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status. Effective screening and timely interventions are essential for reducing bone-related morbidity. Management of long-term bone health requires a broad knowledge base. A multidisciplinary health care team may be needed for optimal assessment and treatment of bone-related issues in patients with cancer. Since publication of the previous NCCN Task Force Report: Bone Health in Cancer Care in 2009, new data have emerged on bone health and treatment, prompting NCCN to convene this multidisciplinary task force to discuss the progress made in optimizing bone health in patients with cancer. In December 2012, the panel members provided didactic presentations on various topics, integrating expert judgment with a review of the key literature. This report summarizes issues surrounding bone health in cancer care presented and discussed during this NCCN Bone Health in Cancer Care Task Force meeting.

show abstract

Section: Nonpharmacologic Componentsmentioning

confidence: 99%

NCCN Task Force Report: Bone Health in Cancer Care

Gralow¹,

Biermann²,

Farooki³

et al. 2013

J Natl Compr Canc Netw

285

176

View full text Add to dashboard Cite

show abstract

“…These acute changes probably reflect a compensatory renal action to maintain serum calcium and phosphate levels in circumstances of androgen deprivation. This finding is clinically relevant, as men treated with androgen deprivation therapy and at increased risk for secondary osteoporosis often have a low dietary calcium and vitamin D intake (32)(33)(34). Treatment with bisphosphonates might thus be less effective under circumstances of combined hypogonadism and low dietary calcium (35).…”

Section: Discussionmentioning

confidence: 99%

Androgen action on renal calcium and phosphate handling: Effects of bisphosphonate treatment and low calcium diet

Khalil

Simitsidellis

Kim

et al. 2020

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Renal calcium and phosphate handling is an important contributor to mineral homeostasis and bone health and the androgen receptor (AR) is highly expressed in the kidney. We investigated the short term effects of androgen deprivation on renal calcium and phosphate reabsorption, independent of their effects on bone. Two weeks following orchidectomy (ORX) of adult mice, bone loss occurred along with hypercalciuria, which was similarly prevented by testosterone and dihydrotestosterone supplementation. Treatment with bisphosphonates prior to ORX also inhibited hypercalciuria, indicating that the calcium flux originated from the bone. Renal calcium and phosphate transporter expression was increased post-ORX, independent of bisphosphonates. Furthermore, androgen deprivation appeared to stimulate local synthesis of 1,25(OH)2D3. When bisphosphonate-treated mice were fed a low calcium diet, bone resorption was no longer blocked and secondary hyperparathyroidism developed, which was more pronounced in ORX mice than sham-operated mice. In conclusion, this study shows that androgen deprivation increased renal calcium and phosphate transporter expression, independent of bone, and underlines the importance of adequate intestinal calcium supply in circumstances of androgen deprivation and bisphosphonate treatment.

show abstract

“…In a community oncology experience, vitamin D deficiency is widespread in cancer patients and correlates with advanced stage disease (Churilla et al, 2012). A high prevalent of vitamin D deficiency has been associated with head and neck cancer (Orell-Kotikangas et al, 2011), breast cancer (Crew et al, 2009;Peppone et al, 2012), vulvar cancer (Salehin et al, 2012), prostate cancer (Varsavsky et al, 2011), pancreatic cancer (Wolpin et al, 2011), gastric cancer (Ren et al, 2012), colon and rectal cancer (Tangrea et al, 1997), ovarian cancer (Lefkowitz et al, 1994), oral cavity and esophagus cancers (Lipworth et al, 2009), myelo-proliferative neoplasms and myelo-dysplastic syndromes (Pardanani et al, 2011), multiple myeloma (Ng et at., 2009), non-Hodgkin's lymphoma (Drake et al, 2010), and chronic lymphocytic leukemia (Shamafelt et al, 2011). On the other hand, a serum 25OHD concentration of 25 nmol/L was associated with a 17% reduction in incidence of cancer, a 29% reduction in total cancer mortality, and a 45% reduction in digestive system cancer mortality (Giovannucci et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

The Impact of Vitamin D in Cancer

Lương¹

2013

Cancer Treatment - Conventional and Innovative Approaches

View full text Add to dashboard Cite

Serum 25 OH vitamin D concentrations and calcium intake are low in patients with prostate cancer

Cited by 11 publications

References 22 publications

NCCN Task Force Report: Bone Health in Cancer Care

NCCN Task Force Report: Bone Health in Cancer Care

Androgen action on renal calcium and phosphate handling: Effects of bisphosphonate treatment and low calcium diet

The Impact of Vitamin D in Cancer

Contact Info

Product

Resources

About